Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2017
Price : $35 *
At a glance
- Drugs Vildagliptin/metformin (Primary) ; Glimepiride; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLOBE
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 31 Aug 2018 Biomarkers information updated
- 04 May 2016 Status changed from recruiting to completed.
- 05 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov record.